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Abstract
Introduction: Small-cell lung cancer (SCLC) is a highly aggressive malignancy with a high potential for growth and spread.
Responses to first-line treatment are common but generally short-lived. Nearly all patients with extensive disease and most
with limited disease relapse. The choice of second-line treatment depends on many factors, including previous treatment,
previous response, time from completion of previous treatment to progression, and performance status. The most common
chemotherapy regimen used in the second-line setting is the one which has led to long-term remission in the first-line
setting. Topotecan monotherapy is increasingly used in second-line treatment, especially in patients with poor performance
status.
Material and methods: Our aim was to evaluate the outcomes of topotecan monotherapy and to determine the effects of
predictive/prognostic factors on the efficacy of the treatment. We investigated 42 patients with SCLC with extensive
disease. Twenty-one subjects received topotecan monotherapy and the remaining ones received other chemotherapy
regimens. Using the Cox proportional hazards model we demonstrated that such factors as the following reduce overall
survival to the greatest degree: age over 65 years (HR = 2.35), anaemia (HR = 1.83), and poor performance status (HR =
1.51). A predictive/prognostic scale was created taking into account 6 factors that were assigned scores depending on the
hazard ratio values.
Results: The survival probability of subjects managed with topotecan was non-significantly higher (P = 0.097) in the group
of subjects who scored less than 10, compared to the group scoring 10 or more on our proposed scale. The scale failed to
prove useful for predicting the course of SCLC in patients receiving other chemotherapy. Objective response to topotecan
was observed in 5 patients (24%).
Conclusions: Precise qualification for topotecan monotherapy may prolong survival and increase the response rate.
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Introduction
Small-cell lung cancer (SCLC) is highly su-
sceptible to chemotherapy, which is the principal
mode of treatment in this tumour type. Chemothe-
rapy in combination with radiotherapy is the stan-
dard of care in limited disease. In extensive dise-
ase, chemotherapy is used and only exceptionally
radiotherapy in the palliative treatment of relap-
ses. In patients with limited disease and complete
response there is a high risk of central nervous
system (CNS) metastases. Elective radiotherapy to
the brain reduces the risk of CNS spread by a half.
The role of elective radiotherapy in patients witho-
ut complete response in the chest and with exten-
sive disease remains unclear [1–3].
The following agents show considerable anti-
cancer activity in first-line chemotherapy: cispla-
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tin, etoposide, cyclophosphamide, doxorubicin,
and vincristine. The most commonly used regi-
mens are the PE regimen (cisplatin plus etoposi-
de), the CE regimen (carboplatin plus etoposide),
or the CAV regimen (cyclophosphamide, doxoru-
bicin plus vincristine). The selection of the PE re-
gimen in the first-line setting is supported by the
synergy of its components, relatively high activi-
ty, and good tolerability. Replacing cisplatin with
carboplatin is not recommended unless clear con-
traindications to the former exist, such as renal
failure. The less frequently used regimens inclu-
de: CAE (cyclophosphamide, doxorubicin plus eto-
poside), V-ICE (carboplatin, iphosphamide, etopo-
side plus vincristine), and VIP-E (carboplatin, ipho-
sphamide, cisplatin plus epirubicin).
Response to chemotherapy is observed in 80–
90% of patients and is usually maintained for seve-
ral months to more than a year. Median overall su-
rvival is 3 months in treatment-naïve patients with
limited disease and 1.5 months in treatment-naïve
patients with extensive disease. Correct treatment
prolongs median survival to 14–20 months in pa-
tients with limited disease and to 9–11 months in
patients with extensive disease [4–6].
First-line treatment means using chemothera-
py in treatment-naïve patients whatever the stage
of the disease. Second-line treatment may be consi-
dered in relapsed patients with good performance
status who have responded to previous first-line
chemotherapy and in patients refractory to first-line
chemotherapy. In patients with a response of more
than 3 months’ duration from the completion of first-
line treatment, the same agents as those in the first-
line setting are used, while patients with early pro-
gression generally receive another combination che-
motherapy or topotecan monotherapy [7].
Topotecan is a topoisomerase I inhibitor
which relieves torsional strain in DNA by inducing
reversible single strand breaks. Topotecan binds
to the topoisomerase I-DNA complex preventing re-
ligation of these single strand breaks and damages
the DNA double-strand structure, leading to cyto-
toxic effects on proliferating cells, including tumo-
ur cells [8].
One of the novel cytostatic agents whose use
in recurrent SCLC seems justified is the synthetic
9-aminoanthracycline amrubicin [9]. Certain ho-
pes are pinned on enhancing the cytotoxic effects
of amrubicin with the c-kit thyrosine kinase inhi-
bitor imatinib. Amrubicin blocks topoisomerase I,
while imatinib prevents phosphorylation of the Akt
kinase, thereby blocking one of the principal si-
gnalling pathways in tumour cells whose activa-
tion is required for cell proliferation and establi-
shing distant metastases. The efficacy of this che-
motherapy has only been demonstrated in in vivo
studies [8, 10].
The aim of our study was to evaluate the out-
comes of second-line treatment with topotecan
monotherapy versus other chemotherapy regimens
in patients with SCLC managed at the Department
of Pneumonology, Oncology, and Allergy, Medical
University in Lublin, Poland, between 2005 and
2009. Another aim of the study was to define sim-
ple clinical predictive/prognostic factors that co-
uld help to qualify patients for topotecan treat-
ment.
Material and methods
The study group comprised 42 patients with
SCLC managed at the Department of Pneumonolo-
gy, Oncology, and Allergy, Medical University in
Lublin, Poland, between May 2005 and March 2009.
This was a retrospective study that concerned
patients managed in real-life conditions. Qualifi-
cation for topotecan treatment or other regimens
was based on the outcome of the first-line treat-
ment of these patients. If a patient had achieved
long-term remission (of more than 3 months’ du-
ration) a platinum-based chemotherapy regimen
was used. If the patient had achieved unsatisfac-
tory response or had developed complications to
platinum-based chemotherapy, topotecan was used
in the second-line treatment.
In the group of patients who did not receive
second-line topotecan, thirteen patients received
platinum-based chemotherapy both in the first- and
second-line settings. In six patients the PE or CE
regimen was replaced by the CAV regimen, and two
patients who had received first-line treatment with
CAV received PE as their second-line treatment.
Twenty-one patients who progressed follo-
wing prior chemotherapy received intravenous
topotecan at the dose of 1.5 mg/m2/day, while the
other 21 patients received other chemotherapy re-
gimens as their second-line treatment. All the pa-
tients had extensive disease when second-line che-
motherapy was being initiated.
Before second-line topotecan and other che-
motherapy regimens were initiated, imaging stu-
dies were performed (plain chest X-ray, chest CT,
and in some cases brain MRI (or CT), whole-body
bone scintigraphy, and abdominal ultrasound).
Before first-line chemotherapy all the patients
in both study groups had their performance status
assessed according to the ECOG/WHO/Zubrod sco-
re. The performance status assessment was repeated
before the initiation of second-line treatment.
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The topotecan-treated group included 6 pa-
tients with brain metastases, 8 with liver metasta-
ses, 2 with brain and liver metastases, and 2 with
kidney metastases. The group receiving other che-
motherapy regimens included 7 patients with li-
ver metastases, 5 with brain metastases, 1 with li-
ver and brain metastases, and 5 with kidney meta-
stases. The remaining patients were classified as
having extensive disease due to the local advan-
cement of the tumour.
The demographic data, performance status,
the first- and second-line regimens (patients with
limited disease received radiotherapy in addition
to chemotherapy), number of chemotherapy cyc-
les, and the time from completion of first-line che-
motherapy to commencement of the second-line
chemotherapy are summarised in Table 1.
Based on laboratory parameters, we checked for
the presence of anaemia (haemoglobin concentration
and erythrocyte counts) and systemic inflammation
(neutrophil absolute and relative counts, lymphocy-
te absolute and relative counts, leukocyte counts, C-
reactive protein [CRP] concentration, and erythrocyte
sedimentation rate [ESR]). We also documented neu-
tropaenia in the first month of second-line treatment
and thrombocytopaenia. We determined the presen-
ce and extent of weight loss within the six months
preceding treatment (Table 1).
Using the Cox proportional hazards model we
demonstrated that six factors reduced overall su-
rvival to the greatest extent. These factors were
assigned scores depending on the hazard ratio
(HR), survival reduction, and the P value. Due to
the small number of patients investigated for esta-
blishing the predictive/prognostic scale, we also
included factors whose effect on survival was non-
significant (P values from 0.10 to 0.25) but whose
HR values exceeded 1.5. Our analysis is therefore
just an estimate and is largely arbitrary. A factor
with P value below 0.05 was assigned 6 points and
the remaining factors were assigned intermediate
scores. We selected the following poor predictive/
prognostic factors for chemotherapy:
— age above 65 years (2 points);
Table 1. Clinical characteristic of examined patients
Topotekan Other II-line chemotherapy
Gender W = 5 W = 3
M = 16 M = 18
Age (years):
mean ± standard deviation 61.6 ± 7.1 62.1± 6.7
median 62 63
Number of patients Topotekan = 21 PE = 6, KE = 3, CAV = 6, KN = 3,
PN = 2, PN, then PE = 1
Disease stage at the I-line treatment beginning LD = 6, ED = 15 LD = 9, ED = 12
Performance status at the start of first line treatment PS0 = 10 PS0 = 8
PS1 = 6 PS1 = 10
PS2 = 5 PS2 = 3
Performance status at the start of second line treatment PS1 = 6 PS0 = 5
PS2 = 15 PS1 = 6
PS2 = 10
Loss of body weight at the start of second line treatment 3–5% = 8 3–5% = 4
> 5% = 7 > 5% = 6
I-line chemotherapy scheme PE = 18, PN = 1, KE = 1, PE = 17, CAV = 2, PE , then
CAV = 1 KE = 1, CAV, then PE = 1
Number of cycles 6 cycles = 3, PE×6 = 2, PE×4 = 1, PE×3 = 1,
5 cycles = 2, PE×2 = 2,
4 cycles = 1, KE×4 = 3,
3 cycles = 3, KN×5 = 1, KN×2 = 1, KN×1 = 1,
2 cycles = 7, CAV×7 = 1, CAV×2 = 2, CAV×1 = 3,
1 cycle = 5 PN×2 = 1, PN×1 = 1, PN/PE×1 = 1
Time between I- and II-line treatment (months)
mean ± standard deviation 3.95 ± 3.093 4.79 ± 3.36
median 3 5
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— weight loss (3–5%: 2 points; >5%: 4 points);
— performance status (PS 0: 0 points; PS 1: 2 po-
ints; PS 2: 4 points);
— time from the completion of first-line chemo-
therapy to the commencement of second-line
chemotherapy (6–12 months: 2 points; 3–6
months: 4 points; <3 months: 6 points);
— anaemia (degree of reduction in haemoglobin
concentration below the lower limit of norm:
2 g/dl: 2 points; 4 g/dl: 4 points; 6 g/dl: 6 po-
ints);
— presence of inflammation (relative neutrophil
count of 70% and WBC of 10–12 thousand/mm3:
2 points; relative neutrophil count of 80%,
WBC exceeding 15 thousand/mm3, elevated
CRP and ESR: 4 points).
We calculated overall survival (OS) from dia-
gnosis to death, and from the commencement of
second-line chemotherapy to death. We employed
the Kaplan-Meier method to estimate the survival
probability depending on the treatment used. We
used the Cox model to calculate HR for survival for
groups of patients differing in terms of demographic
and clinical parameters. The statistical calculations
were performed using Statistica 8.0 software.
Results
Response to first-line treatment was obtained
in 16 patients (76%) receiving topotecan as the
second-line treatment. Stabilisation of the disease
was achieved in 3 patients (14%). Among the pa-
tients receiving other chemotherapy regimens in
the second-line setting, 4 patients achieved stabi-
lisation of the disease, while 10 patients (42.8%)
achieved partial and 3 (14.28%) achieved comple-
te response.
Topotecan treatment led to objective respon-
se in the form of partial remission in 5 patients
(23.8%). Stabilisation of the disease was observed
in 2 other patients. Objective response to topote-
can was only observed in patients who had pre-
viously benefited from first-line treatment. Partial
response to second-line treatment based on other
regimens was only observed in 1 patient, and 4
patients achieved stabilisation of the disease.
Partial response and stabilisation of the dise-
ase following second-line topotecan were signifi-
cantly more common than in the case of other re-
gimens (c2 = 5.56; P < 0.05), while median overall
survival from the commencement of second-line
treatment did not differ significantly between the
study groups (P = 0.59) (Table 2). The survival
probability in both groups was non-significantly
lower in topotecan-treated patients compared to
the other second-line chemotherapy regimens (P
= 0.87) (Fig. 1). In patients with treatment response
or stabilisation of the disease (surviving patients)
median follow-up was 7 months in the topotecan-
treated group and 8 months in the group receiving
other chemotherapy regimens (Table 2).
We used the Cox proportional hazards model
to analyse the effect of selected predictive/progno-
stic factors on the survival of patients receiving
second-line chemotherapy. Having analysed the
individual factors, we found that the following fac-
tors reduced overall survival to the greatest extent:
age below 65 years (HR = 2.35; P = 0.12), anaemia
(HR = 1.83; P < 0.05), and poor performance sta-
tus (HR = 1.15; P = 0.16). Only anaemia signifi-
cantly affected overall survival. In patients rece-
iving other second-line chemotherapy regimens,
the analysed factors did not affect overall survival
from the initiation of treatment.
Based on the above analyses, we assigned the
individual factors appropriate scores depending on
the HR and P values, as described in the “Mate-
rials and methods” section above.
Table 2. Influence of chemotherapy on overall survival observation time in patients with recurrent SCLC
Topotekan Other II-line chemotherapy
Overall surival from diagnosis to death (months), number the death patients 12 17
mean ± standard deviation 13.35 ± 5.7 15.16 ± 8.77
median 12 12
Overall survival from II-line treatment beginning (months) 12 17
mean ± standard deviation 4.81 ± 4.1 4.67 ± 5.92
median 3.5 2
Follow up (months)
mean ± standard deviation 8.22 ± 5.38 12.25 ± 12.31
median 7 8
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We found that the multivariate analysis of the
above factors using the Cox method was not use-
ful in predicting overall survival when the entire
group of patients was analysed (c2 = 3.39; P = 0.75)
and when the analysis was performed in the gro-
up of patients undergoing chemotherapy other than
topotecan treatment (c2 = 3.77; P = 0.71). In the
group of patients receiving topotecan monothera-
py the model affected overall survival in a non-si-
gnificant manner (c2 = 11.09; P = 0.086).
In the case of the entire group of patients (c2
= 0.029; P = 0.86) and the patients receiving che-
motherapy other than topotecan (c2 = 1.89; P =
0.17), overall survival did not depend on our pre-
dictive/prognostic scores. The overall survival of
topotecan-treated patients depended on the predic-
tive/prognostic scoring non-significantly (c2 = 2.41;
P = 0.12) with higher scores adversely affecting the
survival of patients managed with topotecan.
We investigated the distribution of scores
among individual patients. The patients were di-
vided in two groups: patients with scores below the
fiftieth percentile and patients with scores from the
fiftieth percentile up.
The survival probability of topotecan-treated
patients was non-significantly higher (0.097) in the
group of patients achieving 10 or more points on
the proposed predictive/prognostic scale (Fig. 2).
The effects of age (Fig. 3) and anaemia (Fig. 4) on
the survival probability of patients receiving topo-
tecan monotherapy were on the borderline of sta-
tistical significance. Such correlations were not
found in patients receiving other chemotherapy
regimens.
Discussion
Cytotoxic agents affect rapidly-dividing cells,
which is why tumours with high proliferative in-
dex, such as SCLC, are more susceptible to them
than slowly-proliferating ones. A considerable
antitumour activity in SCLC is shown by alkyla-
ting agents (cisplatin, carboplatin, cyclophospha-
mide, iphosphamide), the mechanism of action of
which involves interfering with the biological ac-
tivity of DNA.
It is widely accepted that SCLC is considered
a disseminated disease at the moment of diagno-
sis. One premise for using multidrug chemothera-
py is the presence of tumour cells in different pha-
ses of the cell cycle showing various potential for
proliferation. For this reason combination regimes
result in 30-percent higher rates of objective re-
sponse than monotherapy with platinum agents,
iphosphamide, or etoposide [3, 11].
One exception to this rule is topotecan mono-
therapy in the second-line setting, which is being
increasingly used in recurrent SCLC. The emergen-
ce of tumour cell clones that are resistant to che-
motherapeutic agents used in first-line treatment
Figure 1. Cumulative proportion surviving of SCLC patients treated with topotecan or other second-line chemotherapy
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Figure 2. Cumulative proportion surviving of SCLC patients treated with topotecan depending on points by the scale of therapy predictive
factors
Figure 3. Cumulative proportion surviving of SCLC patients treated with topotecan depending on the patient’s age
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warrants the use of agents with alternative mecha-
nisms of action. Topotecan and irinotecan are syn-
thetic and semisynthetic derivatives of camptothe-
cin, and in contrast to the topoisomerase II inhibi-
tors etoposide and teniposide, they inhibit topo-
isomerase I. Topotecan monotherapy is indicated
as one of the most important second-line treatment
options in patients who have failed on previous
platinum-based combination chemotherapy [12].
The objective response rate in patients with
recurrent SCLC receiving topotecan monothera-
py ranges from 10% to as much as 40% - a consi-
derable improvement in the quality of life and
survival in patients receiving second-line treat-
ment based on topotecan alone versus patients
not receiving chemotherapy [13–15]. Furthermo-
re, many studies suggest a lack of topotecan ac-
cumulation in healthy tissues and a lower seve-
rity of haematological toxicity (granulocytopenia
rate of about 30%, thrombocytopenia rate of abo-
ut 7%, anaemia rate of about 25%) following to-
potecan treatment compared to other cytostatic
agents used in SCLC [16, 17]. The ability of to-
potecan to penetrate the blood-brain barrier is
responsible for the cases of resolved CNS meta-
stases reported in the literature [18]. The results
obtained by various authors are, however, incon-
sistent, which is probably associated with the
differences in the qualification criteria for topo-
tecan treatment [16, 17].
A phase-III study by O’Brien et al. assessed the
efficacy of oral topotecan at the dose of 2.3 mg/m2/
day versus placebo in patients with recurrent SCLC
additionally receiving best supportive care (BSC).
Complete response was achieved in 7% and stabi-
lisation of the disease in 44% of topotecan-treated
patients. Median overall survival was 6.5 months
in topotecan-treated patients and 3.5 in patients
receiving BSC alone. A short period from the com-
pletion of first-line treatment to the commence-
ment of second-line treatment was a poor predic-
tive factor for survival [19].
Subsequently, studies to compare the effica-
cy of topotecan versus other chemotherapy regi-
men in the second-line treatment of SCLC were
performed. A study by Pawel et al. investigated
patients receiving the CAV regimen (n = 104) or
topotecan monotherapy (n = 107) for progres-
sion of the disease following platinum-based
first-line chemotherapy. Response to topotecan
was achieved in 24% of the patients and stabili-
sation in 20% of topotecan-treated patients. Sli-
ghtly inferior responses were observed in CAV-
treated patients: 18% and 20%, respectively.
Median survival in both groups was identical and
equalled 5.5 months [20].
Figure 4. Cumulative proportion surviving of SCLC patients treated with Topotecan depending on anemia symptoms occurrence
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Another phase III study, performed by Eckardt
et al., compared the efficacy of oral (2.3 mg/m2/day)
versus intravenous (1.5 mg/m2/day) topotecan in
recurrent SCLC. A total of 309 patients were en-
rolled. Neither treatment proved superior. The re-
sponse rate and median overall survival was 18.3%
and 9 months, respectively, in the case or oral to-
potecan and 21.9% and 9.5 months, respectively,
in the case of intravenous topotecan [21]. Of note
is the fact that the effect of topotecan treatment in
this study was better than that in the study by
O’Brien et al. and median survival was better than
that in the study by Von Pawel et al.
Ardizzoni et al. observed differences in the
efficacy of topotecan in recurrent SCLC relative to
the susceptibility to first-line chemotherapy. In
susceptible patients achieving remission of more
than 90 days’ duration following first-line treat-
ment, the objective response rate was 38% with
complete responses accounting for as much as
13%. Median overall survival was about 7.5 mon-
ths. The response rate in patients refractory to first-
line cytostatic agents was only 6%, with median
survival of a mere 5 months [16, 22]. Similar fin-
dings were obtained by O’Brien et al. These stu-
dies emphasise the significance of patient selection
to study groups in topotecan efficacy analyses.
In our study the response rate in topotecan-
treated patients was 24% and was high in compa-
rison to the results obtained by other authors. It
should be emphasised, however, that as many as
76% of the patients in this group had achieved
objective response to first-line chemotherapy. This
probably affected the relatively high rate of respon-
se to topotecan, but seemed not to affect the survi-
val. The short duration of remission following first-
line treatment was an important poor predictive
factor in terms of survival in topotecan-treated
patients. The time from the completion of first-line
treatment to the commencement of topotecan mo-
notherapy was included in the scoring system de-
veloped by us for the predictive/prognostic factors.
The median overall survival of patients rece-
iving topotecan was only 3.5 months in our group,
which was probably the result of the heterogenici-
ty of the group, which was composed of patients
with borderline performance status (PS 2/3), which
still allowed them to be qualified for the treatment,
and of patients with distant metastases, including
several patients with metastases in two different
organs. We did not observe any spectacular effica-
cy of topotecan in reducing the sizes of CNS meta-
stases. The median follow-up of surviving patients
who achieved remission or stabilisation of the di-
sease following topotecan treatment was high (7
months). It was a group with good performance
status and with long remissions following first-line
treatment.
The use of topotecan in patients with poorer
performance status (PS 2) and over the age of 65
years is supported by the study by Treat et al, who
observed that the response rate to second-line to-
potecan monotherapy was 14% in patients with
good performance status (n = 381) and even higher
(17%) in patients with poorer performance status
(PS 2; n = 98). However, elderly patients and pa-
tients with poorer performance status experienced
more adverse reactions to chemotherapy (particu-
larly anaemia and thrombocytopenia) and often
required topotecan dose reduction. What is more,
poor performance status was an adverse progno-
stic factor. The median survival was more than 9
months in patients with PS 0, 6.5 months in pa-
tients with PS 1, and only 4 months in patients with
PS 2 [23].
This finding also explains the poor treatment
outcomes we observed in our study. Although the
response rate was high and resulted from the prior
response to first-line chemotherapy, the reduction
in median overall survival was largely associated
with the poor performance status of patients qu-
alified for topotecan treatment. Performance sta-
tus assessment was one of the most important pre-
dictive/prognostic factors.
The classic favourable prognostic factors in
lung cancer patients also include: lack of conside-
rable weight loss, lack of anaemia and lack of im-
mune response abnormalities (both granulocyto-
penia or agranulocytosis and the presence of in-
flammation), normal LDH activity, and age below
70 years [24]. In disseminated disease, further fa-
vourable prognostic factors include solitary meta-
stasis and low local stage of the disease [25]. Most
of these factors were taken into account when we
were developing our predictive/prognostic model
for topotecan-treated patients. We did not use the
latter in our analysis as most patients had been
diagnosed with distant metastases and the local
stage of the disease was high.
Knowing the poor predictive/prognostic fac-
tors, we developed a summary scale that could be
used in predicting the outcomes of second-line tre-
atment of SCLC. As expected, it turned out that
patients receiving topotecan and possessing the
greatest number of adverse predictive/prognostic
factors have poorer prognosis than patients without
these factors. Our scale could not, however, be
employed in patients receiving other second-line
chemotherapy regimens, which was probably a
result of the heterogenicity of the group, principal-
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ly in terms of the differences in second-line thera-
py regimens and the number of completed chemo-
therapy cycles.
Our study confirmed the efficacy of topote-
can in second-line treatment of recurrent SCLC.
The use of multivariate analysis of predictive/
prognostic factors may be useful for qualifying
patients for topotecan treatment. It is a strong ar-
gument in favour of further studies of topotecan
as it is currently an agent with the best-studied
efficacy and tolerability in the treatment of re-
current SCLC [26].
Studies looking into using topotecan in pa-
tients with various stages of SCLC are ongoing.
Eckardt et al. compared the efficacy of two treat-
ment regimens: oral topotecan in combination with
cisplatin (n = 389) versus the classic PE regimen
(n = 395). In both treatment groups the objective
response rate exceeded 60% and median survival
exceeded 10 months. However, the rate of serious
haematological complications was much higher in
topotecan-treated patients than in patients rece-
iving PE (59% vs. 84%) [27].
Recurrent lung cancer is also managed with
dual chemotherapy based on topotecan plus cispla-
tin, paclitaxel, or vincristine. Response rates with
this approach range from 19% to 21%, but median
survival rarely exceeds 4 months. Given the nu-
merous complications, this treatment of recurrent
lung cancer is not superior to topotecan monothe-
rapy [16].
Great hopes are being placed on the novel to-
poisomerase I inhibitor, amrubicin, used for the
treatment of recurrent SCLC. Kair et al. demonstra-
ted that amrubicin monotherapy led to an objecti-
ve response rate of 44.8% in 66 patients and an
increased median survival to 12 months. What is
more, it was possible to achieve treatment respon-
se in the 35.3% of patients who had been refracto-
ry to first-line treatment cytostatic agents [28]. Ino-
ue et al. compared the efficacy of topotecan and
amrubicin in a group of 59 patients and showed
that amrubicin led to treatment response in 17%
of patients previously resistant to chemotherapy,
while no objective response could be achieved with
topotecan in this group [29]. Perhaps in the near
future this agent will replace topotecan in second-
line treatment of SCLC.
Conclusions
1. Objective response to topotecan treatment in
recurrent SCLC is possible in more than 20%
of patients. However, poor performance status,
advanced stage, and the presence of other poor
prognostic factors reduce median survival in to-
potecan-treated patients to less than 4 months.
2. As far as second-line treatment is concerned,
it is possible to identify predictive/prognostic
factors affecting survival following topotecan
treatment. These factors are not as valuable as
in other second-line regimens. It should, ho-
wever, be noted that the analysed groups were
very heterogenous and small. In view of the
above, our predictive/prognostic model did not
significantly affect the overall survival of to-
potecan-treated patients (P = 0.086). Never-
theless, a precise qualification for topotecan
monotherapy may improve the survival and
increase the response rate.
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